Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Quarterly results
Appointed director
Cascadian Therapeutics, Inc. (CASC) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/11/2019 CT ORDER Form CT ORDER - Confidential treatment order:
05/22/2018 CT ORDER Form CT ORDER - Confidential treatment order:
04/09/2018 SC 13G/A Baupost Group reports a 0% stake in Cascadian Therapeutics, Inc.
03/22/2018 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
03/22/2018 EFFECT Form EFFECT - Notice of Effectiveness:
03/22/2018 EFFECT Form EFFECT - Notice of Effectiveness:
03/22/2018 EFFECT Form EFFECT - Notice of Effectiveness:
03/22/2018 EFFECT Form EFFECT - Notice of Effectiveness:
03/19/2018 SC 13D/A Growth Equity Opportunities IV, LLC has filed a Schedule 13D for Cascadian Therapeutics, Inc.
03/09/2018 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Agreement and Plan of Merger, by and among Seattle Genetics, Inc., Valley Acquisition Sub, Inc. and Cascadian Therapeutics, Inc. (incorporated herein by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Cascadian Therapeutics, Inc. on January 31, 2018)"
03/09/2018 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/09/2018 POS462B Form POS462B - Post-effective amendment to registration statement [Rule 462(b)]:
03/09/2018 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/09/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/09/2018 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/09/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/09/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/09/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/09/2018 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/09/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/09/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/09/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/09/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/09/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/09/2018 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
03/09/2018 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
03/09/2018 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
03/08/2018 10-K Annual Report for the period ended December 31, 2017
03/02/2018 SC 13D/A Growth Equity Opportunities IV, LLC reports a 19.7% stake in Cascadian Therapeutics, Inc.
02/26/2018 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
02/16/2018 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
02/16/2018 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
02/14/2018 5 Walker Luke Nathaniel (SVP, Clinical Development) has filed a Form 5 on Cascadian Therapeutics, Inc.
02/13/2018 SC 13G/A Baupost Group reports a 17.2% stake in Cascadian Therapeutics, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy